Home Carboxes 501-81-5
501-81-5,MFCD00066302
Catalog No.:AA00I8VK

501-81-5 | 3-Pyridylacetic acid

Pack Size
Purity
Availability
Price(USD)
Quantity
  
250mg
95%
in stock  
$30.00   $21.00
- +
1g
95%
in stock  
$37.00   $26.00
- +
5g
95%
in stock  
$75.00   $53.00
- +
25g
95%
in stock  
$245.00   $171.00
- +
100g
95%
in stock  
$610.00   $427.00
- +
250g
≥ 99% (HPLC)
in stock  
$1,354.00   $948.00
- +
500g
95%
in stock  
$2,140.00   $1,498.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA00I8VK
Chemical Name:
3-Pyridylacetic acid
CAS Number:
501-81-5
Molecular Formula:
C7H7NO2
Molecular Weight:
137.1360
MDL Number:
MFCD00066302
SMILES:
OC(=O)Cc1cccnc1
NSC Number:
70769
Properties
Computed Properties
 
Complexity:
125  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
10  
Hydrogen Bond Acceptor Count:
3  
Hydrogen Bond Donor Count:
1  
Rotatable Bond Count:
2  
XLogP3:
-0.1  

Literature

Title: Poly[trans-diaquabis-[μ(2)-2-(pyridin-3-yl)acetato-κN:O]-zinc].

Journal: Acta crystallographica. Section E, Structure reports online 20111001

Title: Inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase by lipophilic phosphonates: SAR, QSAR, and crystallographic studies.

Journal: Journal of medicinal chemistry 20110714

Title: Limited expression of cytochrome p450 17α-hydroxylase/17,20-lyase in prostate cancer cell lines.

Journal: Korean journal of urology 20110701

Title: Instability of 2,2-di(pyridin-2-yl)acetic acid. Tautomerization versus decarboxylation.

Journal: Journal of molecular modeling 20110401

Title: Discovery of a 3-pyridylacetic acid derivative (TAK-100) as a potent, selective and orally active dipeptidyl peptidase IV (DPP-4) inhibitor.

Journal: Journal of medicinal chemistry 20110210

Title: New insights into the androgen-targeted therapies and epigenetic therapies in prostate cancer.

Journal: Prostate cancer 20110101

Title: Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

Journal: Bioorganic & medicinal chemistry letters 20101101

Title: An analytical method for the measurement of acid metabolites of tryptophan-NAD pathway and related acids in urine.

Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100415

Title: Analysis of risedronate and related substances by ion-pair reversed-phase high-performance liquid chromatography with evaporative light-scattering detection.

Journal: Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 20100101

Title: CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.

Journal: British journal of cancer 20090310

Title: Reaction of the tobacco alkaloid myosmine with hydrogen peroxide.

Journal: Chemical research in toxicology 20060101

Title: Metabolism of myosmine in Wistar rats.

Journal: Drug metabolism and disposition: the biological fate of chemicals 20051101

Title: Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer.

Journal: British journal of cancer 20040614

Title: Molecular identification of high and low affinity receptors for nicotinic acid.

Journal: The Journal of biological chemistry 20030314

Title: GINOULHIAC E, et al. 3-Pyridineacetic acid and nicotinic acid: blood levels, urinary elimination and excretion of nicotinic acid derivatives in man. Nature. 1962 Mar 10;193:948-9.

Title: Zwickenpflug W, et al. Metabolism of myosmine in Wistar rats. Drug Metab Dispos. 2005 Nov;33(11):1648-56.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Tags:501-81-5 Molecular Formula|501-81-5 MDL|501-81-5 SMILES|501-81-5 3-Pyridylacetic acid